Mycobacterial antigen composition
View Patent ↗There is provided an antigenic composition comprising (a) a first mycobacterial antigenic polypeptide or a first mycobacterial polynucleotide; and (b) a second mycobacterial antigenic polypeptide or a second mycobacterial polynucleotide; wherein: (i) said first mycobacterial antigenic polypeptide comprises a polypeptide sequence having at least 70% amino acid sequence identity to the amino acid sequence of SEQ ID NO: 1 or 7, or a fragment thereof having at least 7 consecutive amino acids thereof; (ii) said first mycobacterial polynucleotide comprises a polynucleotide sequence encoding said first mycobacterial antigenic polypeptide; (iii) said second mycobacterial antigenic polypeptide comprises a polypeptide sequence having at least 70% amino acid sequence identity to the amino acid sequence of SEQ ID NO: 5, or a fragment thereof having at least 7 consecutive amino acids thereof; and (iv) said second mycobacterial polynucleotide comprises a polynucleotide sequence encoding said second mycobacterial polypeptide.
1. A composition comprising: a) a first antibody, wherein said first antibody specifically binds a first mycobacterial antigenic polypeptide within the amino acid sequence of SEQ ID NO: 1; and
(b) a second antibody, wherein said second antibody specifically binds a second mycobacterial antigenic polypeptide within the amino acid sequence of SEQ ID NO: 5; the composition further comprising an adjuvant, an antimicrobial compound, an immunoregulatory agent, or a combination thereof.
2. The composition according to claim 1 , wherein the antibodies are tagged with a detectable label or a functional label.
3. The composition according to claim 1 , further comprising at least one additional antibody, which binds a mycobacterial antigenic polypeptide that is different from said first and second mycobacterial antigenic polypeptides.
4. The composition according to claim 3 , wherein the at least one additional antibody specifically binds within a polypeptide having an amino acid sequence selected from any of SEQ ID NOs: 3, 7, 9-20, 34-44 or 56.
5. The composition according to claim 4 , wherein the at least one additional antibody is tagged with a detectable label or a functional label.
6. The composition according to claim 1 , wherein the composition comprises the adjuvant, and wherein the adjuvant is selected from the group consisting of: complete Freunds adjuvant (CFA), Incomplete Freunds adjuvant (IVA), Saponin, a purified extract fraction of Saporin such as Quil A, a derivative of Saporin such as QS-21, lipid particles based on Saponin such as ISCOM/ISCOMATIX, E. coli heat labile toxin (LT) mutants such as LTK63 and/or LTK72, aluminium hydroxide, N-acetyl-muramyl-L-threonyl-D-isoglutamine (thr-MDP), N-acetyl-nor-muramyl-L-alanyl-D-isoglutamine (CGP 11637, referred to as nor-MDP), N-acetylmuramyl-L-alanyl-D-isoglutaminyl-L-alanine-2-(1′-2′-dipalmitoyl-sn-glycero-3-hydroxyphosphoryl oxy)-ethylamine (CGP 19835A, referred to as MTP-PE), and RIBI, and combinations thereof.
7. A method for producing a therapeutic or prophylactic formulation, the method comprising mixing a pharmaceutically acceptable carrier and at least one component that is an adjuvant, an antimicrobial compound, or an immunoregulatory agent, with:
(a) a first antibody, wherein said first antibody specifically binds a first mycobacterial antigenic polypeptide within the amino acid sequence of SEQ ID NO: 1; and
(b) a second antibody, wherein said second antibody specifically binds a second mycobacterial antigenic polypeptide within the amino acid sequence of SEQ ID NO: 5.
8. The method of claim 7 , wherein the mixing comprises mixing at least two of the components with the pharmaceutically acceptable carrier and the first and the second antibody.
9. A method for producing a therapeutic or prophylactic formulation, the method comprising:
(a) mixing a pharmaceutically acceptable carrier and at least one component that is an adjuvant, an antimicrobial compound, or an immunoregulatory agent, with a first antibody to form a first mixture, wherein the first antibody specifically binds a first mycobacterial antigenic polypeptide within the amino acid sequence of SEQ ID NO: 1; and
(b) mixing a pharmaceutically acceptable carrier and at least one component that is an adjuvant, an antimicrobial compound, or an immunoregulatory agent, with a second antibody to form a second mixture, wherein the second antibody specifically binds a second mycobacterial antigenic polypeptide within the amino acid sequence of SEQ ID NO: 5; and
(c) combining said first mixture and said second mixture to form the therapeutic or prophylactic formulation.